Travelers’ Diarrhea: A Clinical Review

Author(s): Alexander K.C. Leung* , Amy A.M. Leung , Alex H.C. Wong , Kam L. Hon .

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 13 , Issue 1 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Travelers’ diarrhea is the most common travel-related malady. It affects millions of international travelers to developing countries annually and can significantly disrupt travel plans.

Objective: To provide an update on the evaluation, diagnosis, treatment, and prevention of traveler’s diarrhea.

Methods: A PubMed search was completed in Clinical Queries using the key term “traveler’s diarrhea”. The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews. The search was restricted to English literature. Patents were searched using the key term “traveler’s diarrhea” from www.freepatentsonline.com.

Results: Between 10% and 40% of travelers develop diarrhea. The attack rate is highest for travelers from a developed country who visit a developing country. Children are at particular risk. Travelers’ diarrhea is usually acquired through ingestion of food and water contaminated by feces. Most cases are due to a bacterial pathogen, commonly, Escherichia coli, and occur within the first few days after arrival in a foreign country. Dehydration is the most common complication. Pretravel education on hygiene and on the safe selection of food items is important in minimizing episodes. For mild travelers’ diarrhea, the use of antibiotic is not recommended. The use of bismuth subsalicylate or loperamide may be considered. For moderate travelers’ diarrhea, antibiotics such as fluoroquinolones, azithromycin, and rifaximin may be used. Loperamide may be considered as monotherapy or adjunctive therapy. For severe travelers’ diarrhea, antibiotics such as azithromycin, fluoroquinolones, and rifaximin should be used. Azithromycin can be used even for the treatment of dysentery whereas fluoroquinolones and rifaximin cannot be used for such purpose. Recent patents related to the management of travelers’ diarrhea are discussed.

Conclusion: Although travelers’ diarrhea is usually self-limited, many travelers prefer expedient relief of diarrhea, especially when they are traveling for extended periods by air or ground. Judicious use of an antimotility agent and antimicrobial therapy reduces the duration and severity of diarrhea.

Keywords: Antibiotic, antimotility agent, contaminated food, Escherichia coli, oral rehydration, vaccination.

[1]
Ashkenazi S, Schwartz E, O’Ryan M. Travelers’ diarrhea in children: What have we learnt? Pediatr Infect Dis J 2016; 35(6): 698-700.
[http://dx.doi.org/http://dx.doi.org/10.1097/INF.0000000000001145] [PMID: 26986771]
[2]
LaRocque R, Harris JB. Travelers’ diarrhea: Microbiology, epidemiology, and prevention. Available at: https://www.uptodate. com/contents/travelers-diarrhea-microbiology-epidemiology-and-prevention (Accessed on: October 30, 2018).
[3]
Steffen R. Epidemiology of travellers’ diarrhea. J Travel Med 2017; 24: S2-5.
[http://dx.doi.org/http://dx.doi.org/10.1093/jtm/taw072] [PMID: 28520996]
[4]
Leung AK, Robson WL, Davies HD. Traveler’s diarrhea. Adv Ther 2006; 23(4): 519-27.
[http://dx.doi.org/http://dx.doi.org/10.1007/BF02850040] [PMID: 17050494]
[5]
Leggat PA, Goldsmid JM. Travellers’ diarrhoea: Health advice for travellers. Travel Med Infect Dis 2004; 2(1): 17-22.
[http://dx.doi.org/http://dx.doi.org/10.1016/j.tmaid.2004.01.005] [PMID: 17291952]
[6]
Riddle MS, Connor BA, Beeching NJ, DuPont HL, Hamer DH, Kozarsky P, et al. Guidelines for the prevention and treatment of travelers’ diarrhea: A graded expert panel report. J Travel Med 2017; 24: S57-74.
[http://dx.doi.org/http://dx.doi.org/10.1093/jtm/tax060] [PMID: 28521004]
[7]
Steffen R, Hill DR, DuPont HL. Traveler’s diarrhea: A clinical review. JAMA 2015; 313(1): 71-80.
[http://dx.doi.org/http://dx.doi.org/10.1001/jama.2014.17006] [PMID: 25562268]
[8]
Stoney RJ, Han PV, Barnett ED, Wilson ME, Jentes ES, Benoit CM, et al. Travelers’ diarrhea and other gastrointestinal symptoms among Boston-area international travelers. Am J Trop Med Hyg 2017; 96(6): 1388-93.
[http://dx.doi.org/http://dx.doi.org/10.4269/ajtmh.16-0447] [PMID: 28719282]
[9]
Al-Abri SS, Beeching NJ, Nye FJ. Traveller’s diarrhoea. Lancet Infect Dis 2005; 5(6): 349-60.
[http://dx.doi.org/http://dx.doi.org/10.1016/S1473-3099(05)70139-0]] [PMID: 15919621]
[10]
Moore KS. Travelers’ diarrhea: Risk reduction and management. Nurse Pract 2015; 40(11): 1-5.
[http://dx.doi.org/http://dx.doi.org/10.1097/01.NPR.0000472252.51574.26] [PMID: 26474195]
[11]
DuPont HL. Systematic review: The epidemiology and clinical features of travellers’ diarrhoea. Aliment Pharmacol Ther 2009; 30(3): 187-96.
[http://dx.doi.org/http://dx.doi.org/10.1111/j.1365-2036.2009.04028.x] [PMID: 19392866]
[12]
El-Bahnasawy M, Morsy TA. Beyond immunization: Travelers’ infectious diseases. 1-Diarrhea. J Egypt Soc Parasitol 2015; 45(1): 29-42.
[http://dx.doi.org/http://dx.doi.org/10.12816/0010847] [PMID: 26012216]
[13]
Greenwood Z, Black J, Weld L, O’Brien D, Leder K, Von Sonnenburg F, et al. Gastrointestinal infection among international travelers globally. J Travel Med 2008; 15(4): 221-8.
[http://dx.doi.org/http://dx.doi.org/10.1111/j.1708-8305.2008.00203.x] [PMID: 18666921]
[14]
Mattila L, Siitonen A, Kyrönseppä H, Simula I, Oksanen P, Stenvik M, et al. Seasonal variation in etiology of travelers’ diarrhea. J Infect Dis 1992; 165(2): 385-8.
[http://dx.doi.org/http://dx.doi.org/10.1093/infdis/165.2.385] [PMID: 1730905]
[15]
Dunn N, Gossman WG. TravelersDiarrhea.Available at: https://www.ncbi.nlm.nih.gov/books/NBK459348/ (Accessed on: September 18, 2018).
[16]
Duplessis CA, Gutierrez RL, Porter CK. Review: Chronic and persistent diarrhea with a focus in the returning traveler. Trop Dis Travel Med Vaccines 2017; 3: 9.
[http://dx.doi.org/http://dx.doi.org/10.1186/s40794-017-0052-2] [PMID: 28883979]
[17]
Hill DR, Ryan ET. Management of travellers’ diarrhoea. BMJ 2008; 337: a1746.
[http://dx.doi.org/http://dx.doi.org/10.1136/bmj.a1746] [PMID: 18838421]
[18]
Leder K. Advising travellers about management of travellers’ diarrhoea. Aust Fam Physician 2015; 44(1-2): 34-7.
[PMID: 25688957]
[19]
Serichantalergs O, Ruekit S, Pandey P, Anuras S, Mason C, Bodhidatta L, et al. Incidence of Campylobacter concisus and C. ureolyticus in traveler’s diarrhea cases and asymptomatic controls in Nepal and Thailand. Gut Pathog 2017; 9: 47. [http://dx.doi.org/10.1186/s13099-017-0197-6]. [PMID: 28824712].
[20]
Fillion K, Mileno MD. Cholera in travelers: Shifting tides in epidemiology, management, and prevention. Curr Infect Dis Rep 2015; 17(1): 455.
[http://dx.doi.org/http://dx.doi.org/10.1007/s11908-014-0455-4] [PMID: 25604481]
[21]
Jiang ZD, DuPont HL. Etiology of travellers’ diarrhea. J Travel Med 2017; 24(1): S13-6.
[http://dx.doi.org/http://dx.doi.org/10.1093/jtm/tax003] [PMID: 28521001]
[22]
Michal Stevens A, Esposito DH, Stoney RJ, Hamer DH, Flores-Figueroa J, Bottieau E, et al. Clostridium difficile infection in returning travellers. J Travel Med 2017; 24(3)
[http://dx.doi.org/http://dx.doi.org/10.1093/jtm/taw099] [PMID: 28355613]
[23]
Leung AK, Kellner JD, Davies HD. Rotavirus gastroenteritis. Adv Ther 2005; 22(5): 476-87.
[http://dx.doi.org/http://dx.doi.org/10.1007/BF02849868] [PMID: 16418157]
[24]
Simons MP, Pike BL, Hulseberg CE, Prouty MG, Swierczewski BE. Norovirus: New developments and implications for travelers’ diarrhea. Trop Dis Travel Med Vaccines 2016; 2: 1.
[25]
Barrett J, Brown M. Travellers’ diarrhoea. BMJ 2016; 353: i1937.
[26]
Thapa SS, Basnyat B. Chronic diarrhea in a traveler: Cyclosporiasis. Am J Med 2017; 130(12): e535-36.
[http://dx.doi.org/http://dx.doi.org/10.1016/j.amjmed.2017.06.018] [PMID: 28716461]
[27]
Yoshikawa M, Ouji Y, Hirai N, Nakamura-Uchiyama F, Yamada M, Arizono N, et al. Ancylostoma ceylanicum, novel etiological agent for traveler’s diarrhea-report of four Japanese patients who returned from Southeast Asia and Papua New Guinea. Trop Med Health 2018; 46: 6.
[http://dx.doi.org/http://dx.doi.org/10.1186/s41182-018-0087-8] [PMID: 29563849]
[28]
Camilleri M, Nullens S, Nelsen T. Enteroendocrine and neuronal mechanisms in pathophysiology of acute infectious diarrhea. Dig Dis Sci 2012; 57(1): 19-27.
[http://dx.doi.org/http://dx.doi.org/10.1007/s10620-011-1939-9] [PMID: 22001941]
[29]
Muanprasat C, Chatsudthipong V. Cholera: Pathophysiology and emerging therapeutic targets. Future Med Chem 2013; 5(7): 781-98.
[http://dx.doi.org/http://dx.doi.org/10.4155/fmc.13.42] [PMID: 23651092]
[30]
Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004; 363(9404): 223-33.
[http://dx.doi.org/http://dx.doi.org/10.1016/S0140-6736(03)15328-7] [PMID: 14738797]
[31]
Mirhoseini A, Amani J, Nazarian S. Review on pathogenicity mechanism of enterotoxigenic Escherichia coli and vaccines against it. Microb Pathog 2018; 117: 162-9.
[http://dx.doi.org/http://dx.doi.org/10.1016/j.micpath.2018.02.032] [PMID: 29474827]
[32]
Field M. Intestinal ion transport and the pathophysiology of diarrhea. J Clin Invest 2003; 111(7): 931-43.
[http://dx.doi.org/http://dx.doi.org/10.1172/JCI200318326] [PMID: 12671039]
[33]
Hoque KM, Chakraborty S, Sheikh IA, Woodward OM. New advances in the pathophysiology of intestinal ion transport and barrier function in diarrhea and the impact on therapy. Expert Rev Anti Infect Ther 2012; 10(6): 687-99.
[http://dx.doi.org/http://dx.doi.org/10.1586/eri.12.47]. ] [PMID: 22734958]
[34]
LaRocque R, Harris JB. Travelers’ diarrhea: Clinical manifestations, diagnosis, and treatment. Available at: https://www. uptodate.com/contents/travelers-diarrhea-clinical-manifestations-diagnosis-and-treatment(Accessed on September 30, 2018)
[35]
Connor BA, Rogova M, Whyte O. Use of a multiplex DNA extraction PCR in the identification of pathogens in travelers’ diarrhea. J Travel Med 2018; 25(1) [http://dx.doi.org/10.1093/jtm/tax087]. [PMID: 29394385].
[36]
Connor BA. Multiplex PCR testing for travelers’ diarrhea-friend or foe? Int J Infect Dis 2018; 66: 96-8. [http://dx.doi.org/10.1016/j.ijid.2017.11.022]. [PMID: 29175449].
[37]
Hamer DH. Multiplex PCR for determining aetiology of travellers’ diarrhoea: Too much information or too little? J Travel Med 2018; 25(1)
[http://dx.doi.org/http://dx.doi.org/10.1093/jtm/tax089] [PMID: 29394386]
[38]
Vila J. New molecular diagnostic tools in traveller’s diarrhea. J Travel Med 2017; 24: S23-8.
[39]
Leung AK, Darling P, Auclair C. Oral rehydration therapy- A review. J R Soc Health 1987; 107(2): 64-7.
[http://dx.doi.org/http://dx.doi.org/10.1177/146642408710700210] [PMID: 3108503]
[40]
Leung AK, Robson WL. Acute diarrhea in children: What to do and what not to do. Postgrad Med 1989; 86(8): 161-164, 167-174.
[http://dx.doi.org/http://dx.doi.org/10.1080/00325481.1989.11704505] [PMID: 2685791]
[41]
Mera V, López T, Serralta J. Take traveller’s diarrhoea to heart. Travel Med Infect Dis 2007; 5(3): 202-3.
[http://dx.doi.org/http://dx.doi.org/10.1016/j.tmaid.2006.11.001] [PMID: 17448951]
[42]
Robson WL, Leung AK, Fick GH. Bloody diarrhea in hemolytic uremic syndrome. Child Nephrol Urol 1991; 11(4): 234-5.
[PMID: 1777908]
[43]
Robson WL, Leung AK, Trevenen CL, Brant R. Diarrhea-associated hemolytic uremic syndrome. Can Fam Physician 1993; 39: 2139-45.
[PMID: 8219861]
[44]
Robson WL, Leung AK, Miller-Hughes DJ. Recurrent hemorrhagic colitis caused by Escherichia coli O157: H7. Pediatr Infect Dis J 1993; 12(8): 699-701.
[http://dx.doi.org/http://dx.doi.org/10.1097/00006454-199308000-00018] [PMID: 8414787]
[45]
Robson WL, Leung AK. The hemolytic-uremic syndrome and Escherichia coli O157: H7 infection. Ann Intern Med 1993; 119(3): 249-50.
[http://dx.doi.org/http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00025] [PMID: 8323100]
[46]
Robson WL, Leung AK, Kaplan BS. Hemolytic-uremic syndrome. Curr Probl Pediatr 1993; 23(1): 16-33.
[http://dx.doi.org/http://dx.doi.org/10.1016/0045-9380(93)90027-A] [PMID: 8453889]
[47]
Schwille-Kiuntke J, Enck P, Polster AV, Gaile M, Kremsner PG, Zanger P. Postinfectious irritable bowel syndrome after travelers’ diarrhea- A cohort study. Neurogastroenterol Motil 2015; 27(8): 1147-55.
[http://dx.doi.org/http://dx.doi.org/10.1111/nmo.12601] [PMID: 26009981]
[48]
Wagner A, Wiedermann U. Travellers’ diarrhoea- Pros and cons of different prophylactic measures. Wien Klin Wochenschr 2009; 121: 13-8.
[http://dx.doi.org/http://dx.doi.org/10.1007/s00508-009-1228-1] [PMID: 19915810]
[49]
Chow CM, Leung AK, Hon KL. Acute gastroenteritis: From guidelines to real life. Clin Exp Gastroenterol 2010; 3: 97-112.
[http://dx.doi.org/http://dx.doi.org/10.2147/CEG.S6554] [PMID: 21694853]
[50]
Issenman RM, Leung AK. Oral and intravenous rehydration of children. Can Fam Physician 1993; 39: 2129-36.
[PMID: 8219860]
[51]
Leung AK, Sauve RS. Breast is best for babies. J Natl Med Assoc 2005; 97(7): 1010-9.
[PMID: 16080672]
[52]
Libman M. CATMAT. Summary of the Committee to Advise on Tropical Medicine and Travel (CATMAT) Statement on Travellers’ Diarrhea. Can Commun Dis Rep 2015; 41(11): 272-84.
[http://dx.doi.org/http://dx.doi.org/10.14745/ccdr.v41i11a03] [PMID: 29769922]
[53]
Lääveri T, Sterne J, Rombo L, Kantele A. Systematic review of loperamide: No proof of antibiotics being superior to loperamide in treatment of mild/moderate travellers’ diarrhea. Travel Med Infect Dis 2016; 14(4): 299-312.
[http://dx.doi.org/http://dx.doi.org/10.1016/j.tmaid.2016.06.006] [PMID: 27363327]
[54]
Ericsson CD, Riddle MS. Should travel medicine practitioners prescribe antibiotics for self-treatment of travelers' diarrhea? J Travel Med 2018; 1; 25(1)
[http://dx.doi.org/[http://dx.doi.org/10.1093/jtm/tay081]] [PMID: 30184202]
[55]
Pinos Y, Ruiz MI, Corsi Ó, Rada G. Is it worth adding loperamide to antibiotic treatment of traveler’s diarrhea? Medwave 2017; 17e6958
[http://dx.doi.org/http://dx.doi.org/10.5867/medwave.2017.6958] [PMID: 28549055]
[56]
Heather CS. Travellers' diarrhoea. BMJ Clin Evid 2015; pii: 0901
[57]
Leung AK, Robson WL. Acute gastroenteritis in children: Role of anti-emetic medication for gastroenteritis-related vomiting. Paediatr Drugs 2007; 9(3): 175-84.
[http://dx.doi.org/http://dx.doi.org/10.2165/00148581-200709030-00006] [PMID: 17523698]
[58]
Leung AK, Robson WL. In children with vomiting related to acute gastroenteritis, are antiemetic medications an effective adjunct to fluid and electrolyte therapy?: Part A: Evidence-based answer and summary. Paediatr Child Health 2008; 13(5): 391-4.
[http://dx.doi.org/http://dx.doi.org/10.1093/pch/13.5.391] [PMID: 19412369]
[59]
Leung AK, Robson WL. In children with vomiting related to acute gastroenteritis, are antiemetic medications an effective adjunct to fluid and electrolyte therapy?: Part B: Clinical commentary. Paediatr Child Health 2008; 13(5): 393-4.
[http://dx.doi.org/http://dx.doi.org/10.1093/pch/13.5.393] [PMID: 19412370]
[60]
De Bruyn G, Hahn S, Borwick A. Antibiotic treatment for travellers’ diarrhoea. Cochrane Database Syst Rev 2000; (3): CD002242
[PMID: 10908534]
[61]
McDonald LC. Effects of short- and long-course antibiotics on the lower intestinal microbiome as they relate to traveller’s diarrhea. J Travel Med 2017; 24: S35-8.
[http://dx.doi.org/http://dx.doi.org/10.1093/jtm/taw084] [PMID: 28520993]
[62]
DuPont HL. Systematic review: Prevention of travellers’ diarrhoea. Aliment Pharmacol Ther 2008; 27(9): 741-51.
[http://dx.doi.org/http://dx.doi.org/10.1111/j.1365-2036.2008.03647.x] [PMID: 18284650]
[63]
Kogawa AC, Salgado HRN. Status of rifaximin: A review of characteristics, uses and analytical methods. Crit Rev Anal Chem 2018; 48(6): 459-66.
[http://dx.doi.org/http://dx.doi.org/10.1080/10408347.2018.1447355] [PMID: 29580065]
[64]
Layer P, Andresen V. Review article: Rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers’ diarrhoea. Aliment Pharmacol Ther 2010; 31(11): 1155-64.
[http://dx.doi.org/http://dx.doi.org/10.1111/j.1365-2036.2010.04296.x] [PMID: 20331580]
[65]
Bae JM. Prophylactic efficacy of probiotics on travelers’ diarrhea: An adaptive meta-analysis of randomized controlled trials. Epidemiol Health 2018; 40e2018043
[http://dx.doi.org/http://dx.doi.org/10.4178/epih.e2018043] [PMID: 30189723]
[66]
Pinos Y, Castro-Gutiérrez V, Rada G. Are probiotics effective to prevent traveler’s diarrhea? Medwave 2016; 16e6807
[http://dx.doi.org/[http://dx.doi.org/10.5867/medwave.2016.6807].]
[67]
McFarland LV, Goh S. Are probiotics and prebiotics effective in the prevention of travellers' diarrhea: A systematic review and meta-analysis. Travel Med Infect Dis 2018; pii: S1477-8939(18): 30258-8.
[http://dx.doi.org/[http://dx.doi.org/10.1016/j.tmaid.2018.09.007]]
[68]
Hasle G, Raastad R, Bjune G, Jenum PA, Heier L. Can a galacto-oligosaccharide reduce the risk of traveller’s diarrhoea? A placebo-controlled, randomized, double-blind study. J Travel Med 2017; 24(5)
[http://dx.doi.org/http://dx.doi.org/10.1093/jtm/tax057] [PMID: 28931149]
[69]
Evans DP. Non-pharmacotherapeutic interventions in travellersdiarrhoea (TD). J Travel Med 2018; 25: S38-45.
[http://dx.doi.org/http://dx.doi.org/10.1093/jtm/tay013] [PMID: 29718436]
[70]
Mokomane M, Kasvosve I, de Melo E, Pernica JM, Goldfarb DM. The global problem of childhood diarrhoeal diseases: Emerging strategies in prevention and management. Ther Adv Infect Dis 2018; 5(1): 29-43.
[http://dx.doi.org/http://dx.doi.org/10.1177/2049936117744429] [PMID: 29344358]
[71]
Taylor DN, Hamer DH, Shlim DR. Medications for the prevention and treatment of travellers’ diarrhea. J Travel Med 2017; 24: S17-22.
[http://dx.doi.org/http://dx.doi.org/10.1093/jtm/taw097] [PMID: 28520998]
[72]
Ng QX, Ho CYX, Shin D, Venkatanarayanan N, Chan HW. A meta-analysis of the use of rifaximin to prevent travellers’ diarrhoea. J Travel Med 2017; 24(5): 1-5.
[http://dx.doi.org/http://dx.doi.org/10.1093/jtm/tax025] [PMID: 28498921]
[73]
Neilson AA, Mayer CA. Cholera - Recommendations for prevention in travellers. Aust Fam Physician 2010; 39(4): 220-6.
[PMID: 20372681]
[74]
Ahmed T, Bhuiyan TR, Zaman K, Sinclair D, Qadri F. Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea. Cochrane Database Syst Rev 2013; (7): CD009029
[http://dx.doi.org/http://dx.doi.org/10.1002/14651858.CD009029.pub2] [PMID: 23828581]
[75]
Torrell JM, Aumatell CM, Ramos SM, Mestre LG, Salas CM. Reduction of travellers’ diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers. Vaccine 2009; 27(30): 4074-7.
[http://dx.doi.org/http://dx.doi.org/10.1016/j.vaccine.2009.04.025] [PMID: 19376179]
[76]
López-Gigosos R, García-Fortea P, Reina-Doña E, Plaza-Martín E. Effectiveness in prevention of travellers’ diarrhoea by an oral cholera vaccine WC/rBS. Travel Med Infect Dis 2007; 5(6): 380-4.
[http://dx.doi.org/http://dx.doi.org/10.1016/j.tmaid.2007.06.001] [PMID: 17983977]
[77]
Wong KK, Burdette E, Mahon BE, Mintz ED, Ryan ET, Reingold AL. Recommendations of the Advisory Committee on Immunization Practices for use of cholera vaccine. MMWR Morb Mortal Wkly Rep 2017; 66(18): 482-5.
[http://dx.doi.org/http://dx.doi.org/10.15585/mmwr.mm6618a6] [PMID: 28493859]
[78]
Mosley JF 2nd, Smith LL, Brantley P, Locke D, Como M. Vaxchora: The first FDA-approved cholera vaccination in the United States. P&T 2017; 42(10): 638-40.
[PMID: 29018300]
[79]
Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, et al. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin Infect Dis 2016; 62(11): 1329-35.
[http://dx.doi.org/http://dx.doi.org/10.1093/cid/ciw145] [PMID: 27001804]
[80]
Kabir S. Critical analysis of compositions and protective efficacies of oral killed cholera vaccines. Clin Vaccine Immunol 2014; 21(9): 1195-205.
[http://dx.doi.org/http://dx.doi.org/10.1128/CVI.00378-14] [PMID: 25056361]
[81]
Baik YO, Choi SK, Olveda RM, Espos RA, Ligsay AD, Montellano MB, et al. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines. Vaccine 2015; 33(46): 6360-5.
[http://dx.doi.org/http://dx.doi.org/10.1016/j.vaccine.2015.08.075] [PMID: 26348402]
[82]
Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: A cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2013; 13(12): 1050-6.
[http://dx.doi.org/http://dx.doi.org/10.1016/S1473-3099(13)70273-1] [PMID: 24140390]
[83]
Moro PL, Sukumaran L. Cholera vaccination: Pregnant women excluded no more. Lancet Infect Dis 2017; 17(5): 469-70.
[http://dx.doi.org/http://dx.doi.org/10.1016/S1473-3099(17)30055-5] [PMID: 28161571]
[84]
Ni Y, Springer MJ, Guo J, Finger-Baker I, Wilson JP, Cobb RR, et al. Development of a synthetic Vi polysaccharide vaccine for typhoid fever. Vaccine 2017; 35(51): 7121-6.
[http://dx.doi.org/http://dx.doi.org/10.1016/j.vaccine.2017.10.081] [PMID: 29150208]
[85]
Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2018; 5CD001261
[PMID: 29851031]
[86]
Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354(1): 11-22.
[http://dx.doi.org/http://dx.doi.org/10.1056/NEJMoa052434] [PMID: 16394298]
[87]
Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354(1): 23-33.
[http://dx.doi.org/http://dx.doi.org/10.1056/NEJMoa052664] [PMID: 16394299]
[88]
Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. Vaccine 2014; 32(Suppl. 1): A110-6.
[http://dx.doi.org/http://dx.doi.org/10.1016/j.vaccine.2014.04.079] [PMID: 25091663]
[89]
Praharaj I, Platts-Mills JA, Taneja S, Antony K, Yuhas K, Flores J, et al. Diarrheal etiology and impact of co-infections on rotavirus vaccine efficacy estimates in a clinical trial of a monovalent human-bovine (116E) oral rotavirus vaccine, Rotavac, India. Clin Infect Dis 2018. [Epub ahead of print].
[http://dx.doi.org/http://dx.doi.org/10.1093/cid/ciy896] [PMID: 30335135]
[90]
Goldsmid JM, Leggat PA. The returned traveller with diarrhoea. Aust Fam Physician 2007; 36(5): 322-7.
[PMID: 17492065]
[91]
Leung AK, Robson WL. Evaluating the child with chronic diarrhea. Am Fam Physician 1996; 53(2): 635-43.
[PMID: 8629543]
[92]
Giuntini S, Stoppato M, Sedic M, Ejemel M, Pondish JR, Wisheart D, et al. Identification and characterization of human monoclonal antibodies for immunoprophylaxis against enterotoxigenic Escherichia coli infection. Infect Immun 2018; pii: IAI.00355-18 [Epub ahead of print]
[http://dx.doi.org/doi: 10.1128/IAI.00355-18]
[93]
Rojas-Lopez M, Monterio R, Pizza M, Desvaux M, Rosini R. Intestinal pathogenic Escherichia coli: Insights for vaccine development. Front Microbiol 2018; 9: 440.
[http://dx.doi.org/http://dx.doi.org/10.3389/fmicb.2018.00440] [PMID: 29615989]
[94]
Huang J, Duan Q, Zhang W. Significance of enterotoxigenic Escherichia coli (ETEC) heat-labile toxin (LT) enzymatic subunit epitopes in LT enterotoxicity and immunogenicity. Appl Environ Microbiol 2018; 84(15): e00849-18.
[http://dx.doi.org/http://dx.doi.org/10.1128/AEM.00849-18] [PMID: 29802193]
[95]
Walker RI, Wierzba TF, Mani S, Bourgeois AL. Vaccines against Shigella and enterotoxigenic Escherichia coli: A summary of the 2016 VASE Conference. Vaccine 2017; 35(49 Pt A): 6775-82.
[http://dx.doi.org/http://dx.doi.org/10.1016/j.vaccine.2017.09.045] [PMID: 28987444]
[96]
Borde A, Ekman A, Larsson A, Carlin N, Holmgren J, Tobias J. Preparation and preclinical evaluation of a freeze-dried formulation of a novel combined multivalent whole-cell/B-subunit oral vaccine against enterotoxigenic Escherichia colidiarrhea. Eur J Pharm Biopharm 2016; 108: 18-24.
[http://dx.doi.org/http://dx.doi.org/10.1016/j.ejpb.2016.07.011] [PMID: 27485398]
[97]
Isanaka S, Guindo O, Langendorf C, Matar Seck A, Plikaytis BD, Sayinzoga-Makombe N, et al. Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger. N Engl J Med 2017; 376(12): 1121-30.
[http://dx.doi.org/http://dx.doi.org/10.1056/NEJMoa1609462] [PMID: 28328346]
[98]
Mitra M, Shah N, Ghosh A, Chatterjee S, Kaur I, Bhattacharya N, et al. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study. Hum Vaccin Immunother 2016; 12(4): 939-45.
[http://dx.doi.org/http://dx.doi.org/10.1080/21645515.2015.1117715] [PMID: 26901576]
[99]
Sack DA, Zhang W. Multiepitope fusion antigens and vaccines and their use in treatment of enterogenic diarrhea. US20160317638 (2016).
[100]
Savkovic S, Roy HK. Prophylaxis and treatment of enteropathogenic bacterial infection. US20140057993 (2014).
[101]
Savarino SJ. Adhesin as immunogen against enterotoxigenic Escherichia coli. US20150266932 (2015).
[102]
Rao DR, Kankan RN, Phull MS, Ghagare M. Rifaximin. US20160374999 . (2016).
[103]
Ghagare MG, Saroj SP, Rao DR, Kankan RN. Rifaximin complexes. US20180289817. (2018).
[104]
Driessen WE. Composition and methods for treating traveler's diarrhea. US20180296628. (2018).
[105]
Cheng SX. Materials and methods for prevention and treatment of diarrhea and inflammation of the gastrointestinal tract. US20180271903. (2018).
[106]
Lefevre JM, Renaud G, Le Guern ME. Composition and methods for preventing infections. US20180153947. (2018).


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 1
Year: 2019
Page: [38 - 48]
Pages: 11
DOI: 10.2174/1872213X13666190514105054

Article Metrics

PDF: 23
HTML: 2
EPUB: 1
PRC: 1